ENDPOINTS

#ASCO25: Pfizer's Braftovi combo doubles survival time for some colorectal cancer patients

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death by half for certain colorectal cancer patients, according to results from a Phase 3 trial. The combination of Braftovi ...

May 30, 2025 - 13:04
 0
#ASCO25: Pfizer's Braftovi combo doubles survival time for some colorectal cancer patients
Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death by half for certain colorectal cancer patients, according to results from a Phase 3 trial. The combination of Braftovi ...
Read More

Tags:

Previous Article

Why we forget our childhoods

Next Article

Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Da...

Related Posts

Where to Buy Quality Used Acura Engines in Florida

May 12, 2025  0

#ASCO25: Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

#ASCO25: Arvinas, Pfizer's PROTAC in breast cancer no b...

May 31, 2025  0

Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences

Astellas licenses Claudin18.2 ADC from China’s Evopoint...

May 30, 2025  0